InterVenn Biosciences

InterVenn is a life science company decoding the glycoproteome to power personalized, predictive, and preventive care.

[InterVenn Biosciences @InterVennBioSci]

Did you miss our ESMO presentation? Listen to this interview with Dr. David Braun on Uro Today, where he explains how our glycoproteomic platform, GlycoVision, can lead to the discovery of predictive and prognostic biomarkers for checkpoint inhibitors.
https://t.co/jZfPiwxBvv

[InterVenn Biosciences @InterVennBioSci]

Headed to ESMO 2024? Join us this Sunday to see truly exciting results generated using InterVenn's glycoproteomic biomarker discovery platform, GlycoVision.

#glycoproteomics #biomarkerdiscovery #ESMO2024

[InterVenn Biosciences @InterVennBioSci]

Don't miss out on this exciting opportunity to utilize our proprietary glycoproteomics-based platform, GlycoVision™. Apply by tomorrow, August 16th! ⏰

https://t.co/QxVLBVT8Wk

[InterVenn Biosciences @InterVennBioSci]

⏰ Time is running out! Apply to our Glycoproteomic Innovator Grant before August 16th!
https://t.co/xXWVbcxHUd

#ResearchGrant #Glycoproteomics #CancerResearch #Biotech

[InterVenn Biosciences @InterVennBioSci]

Apply today to our Glycoproteomic Innovator Grant! This grant provides a unique opportunity for researchers to leverage our GlycoVision™ Platform to analyze up to 200 human serum or plasma samples. Learn more:
https://t.co/xXWVbcxHUd
#CancerResearch #Grants #Glycoproteomics

[InterVenn Biosciences @InterVennBioSci]

Immune checkpoint inhibitors are powerful therapeutics in the fight against cancer, but not all patients respond. Glycoproteins show promise as prognostic and predictive #biomarkers for patient outcomes.

Read the article: https://t.co/AavhM0f85T

#Immunotherapy #Pharma

[InterVenn Biosciences @InterVennBioSci]

Calling all academic researchers! Apply to our inaugural Glycoproteomic Innovator Grant. This grant provides a unique opportunity for researchers to leverage our GlycoVision™ Platform to analyze up to 200 human serum or plasma samples. Learn more: https://t.co/xXWVbcxHUd

[InterVenn Biosciences @InterVennBioSci]

Want a crash course in glycoproteomics? We've got you covered. In this video, you'll learn the role of glycoproteomics in disease research, drug development and personalized medicine and understand why we're passionate about studying this layer of biology.
https://t.co/9jHHOiOZUB

[InterVenn Biosciences @InterVennBioSci]

Join us in listening to our bioinformatics expert, Matthew Campbell, PhD, speak at the @neo4j LifeScience hybrid event on June 12 at 9:00 EDT | 13:00 BST | 14:00 CEST | 18:30 IST!

Register here: https://t.co/7uRqQBjTDN

#glycobiology #knowledgegraph

[InterVenn Biosciences @InterVennBioSci]

Will you be at #ASCO May 31 - June 4 in Chicago? Schedule a meeting with Miles McKenna, Director of BD, to learn more about our glycoproteomic biomarker discovery services. See you there!

[InterVenn Biosciences @InterVennBioSci]

In our latest study we demonstrate that blood-based glycopeptide biomarkers have the potential to distinguish benign from malignant pelvic masses, and early- from late-stage epithelial ovarian cancer (EOC).

https://t.co/GbmMcixs6r
#EarlyDetection #OvarianCancer #Glycoproteomics

[InterVenn Biosciences @InterVennBioSci]

Press coverage by News Medical (https://t.co/w407OkqV53) highlights our recent paper in the British Journal of Cancer that explores the potential utility of glycoproteins as biomarkers of epithelial #ovarian #cancer.
📗 Read more: https://t.co/FZNDRI6ClG
#Glyco #Biotech #EOC

[InterVenn Biosciences @InterVennBioSci]

📢 Don't miss out! This Tuesday, join our live webinar to learn how protein #glycosylation analysis can provide new insights into disease biology and therapeutic response.
📆 Tuesday, April 30th, 2024
⏰ 11:00am PT / 2:00pm ET
Register here: https://t.co/ZSulP3d6eW
#biotech

[InterVenn Biosciences @InterVennBioSci]

We're excited to introduce the panel for our upcoming webinar on "Unlocking the Glycoproteome: Utilizing a Robust AI/ML Based Platform for Biomarker Discovery." Don't miss this opportunity to gain insights from these industry leaders! Register now: https://t.co/94Y7wq4YzN

[InterVenn Biosciences @InterVennBioSci]

Our recent groundbreaking study demonstrates not only the feasibility of glycoproteomic approaches in identifying glycoproteins with polyLacNAc motifs, but also paves the way for deeper exploration of their roles in #cancer #biology.
Read more: https://t.co/76hGTVwxUB

[InterVenn Biosciences @InterVennBioSci]

Join us for a webinar: "Unlocking the Glycoproteome: Utilizing a Robust AI/ML Based Platform for Biomarker Discovery." Sign up today!

📅 Date: April 30th, 2024
🕒 Time: 2:00pm ET
🔗 Register: https://t.co/Cekrn4Alpv

#Glycoproteomics #BiomarkerDiscovery #Webinar #CancerResearch

[InterVenn Biosciences @InterVennBioSci]

Screening rates of colon cancer #CRC in the US are below national targets.

That’s why we’re developing a blood-based test to detect the early warning signs of CRC and make screening easy.

https://t.co/asItqQwcxq

#ColorectalCancerAwarenessMonth #PrecisionMedicine

[InterVenn Biosciences @InterVennBioSci]

What can glycoproteomic analysis reveal in your research?

Learn more about our discovery platform and the pharma services we offer: https://t.co/zpdqmKM9Q0

#pharma #glycoproteomics #precisionmedicine #biotech

[InterVenn Biosciences @InterVennBioSci]

Check out the March issue of Life Science Alliance: we're on the cover! A claw machine is used to artistically illustrate the selectivity of an anti-PD-1 antibody for fucosylated variants (red pyramids) of PD-1.

Congrats to the team on this achievement!

https://t.co/SbadWylcgQ

[InterVenn Biosciences @InterVennBioSci]

Our latest study, “Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors”, emphasizes the key role that glycoprofiling can play in drug and #biomarker development.

Read the full paper: https://t.co/a3P7v9x6ES

#glycoproteomics #PD1 #pharma